Rheumatoid Arthritis eJournal Club
   

Quantitatively-Driven Management of Rheumatoid Arthritis
 
Release Date: October 1, 2009 Expiration Date: October 1, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion 1 hour
Description / Overview The purpose of this activity is to discuss evidence supporting quantitatively-driven treatment decisions, or “treat to a target,” for a patient with rheumatoid arthritis (RA).
Objectives On completion of this activity, participants should be able to:
  1. Assess dichotomous and continuous measures of RA disease activity, relating disease activity scores to the level of disease activity.
  2. Discuss clinical trial evidence supporting quantitatively-driven treatment decisions for patients with RA.
  3. Recognize the value of implementing quantitatively-driven assessment of RA disease activity into clinical practice.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty Jonathan Kay, MD
Professor of Medicine
Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Worcester, Massachusetts
Faculty Disclosure In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
Leonard Calabrese, DO
  Consulting: Abbott Laboratories; Amgen Inc.; Centocor, Inc.; Elan Pharmaceuticals, Inc.; Genentech, Inc.; Roche Laboratories, Inc.
 
  Research: Centocor, Inc.
 
  Teaching and Speaking: Amgen Inc.; Genentech, Inc.
 
Jonathan Kay, MD
  Consulting: Centocor Ortho Biotech Services, LLC; UCB; sanofi-aventis Group; Wyeth Pharmaceuticals
 
  Independent Contractor: Centocor Ortho Biotech Services, LLC; Genentech, Inc.
 
  Teaching and Speaking: Bristol-Myers Squibb Company Norway

The Cleveland Clinic Foundation Center for Continuing Education acknowledges:

This activity is supported by an educational donation provided by Amgen.
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
This activity is supported by an educational grant from Centocor Ortho Biotech Services.
This activity is supported by an independent educational grant from Roche Laboratories, Inc.

This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education,
the RJ Fasenmyer Center for Clinical Immunology and DIME.

CME Disclaimer